



ALK
Investor Relations Department
BÅ,ge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)

Sign-up for Email alerts [↗](#)

OMX: ALKB

| | |
|---------------|----------------------------|
| Last Trade: | 912.50 |
| Trade Time: | 4:59 PM ET Nov 22, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 839.00 - 1133.00 |
| Volume | 843,300 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Nov 10, 2017

[Nine-month interim report \(Q3\) 2017](#)

Nov 3, 2017

[ALK appoints Søren Jelert as new Chief Financial Officer](#)

Nov 3, 2017

[Release date of nine-month interim report \(Q3\) 2017 and audio cast](#)

Oct 12, 2017

[Notification of ownership in ALK](#)

Sep 27, 2017

[ALK's partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan](#)

Upcoming Events [\[View all \]](#)

Dec 5, 2017

[Carnegie Healthcare Day, New York](#)

Dec 11, 2017

[Danske Bank Copenhagen Winter Seminar](#)